Thu.Mar 07, 2024

article thumbnail

Boehringer Ingelheim cuts monthly out-of-pocket inhaler prices to $35 for US patients

Fierce Pharma

As one of Boehringer Ingelheim's asthma competitors catches scrutiny over pricing and access concerns, the company itself is taking steps to cut patient costs in the U.S. | Starting on June 1, patients will only have to shell out a maximum of $35 per month for Boehringer Ingelheim inhalers in the U.S.

Patients 299
article thumbnail

Answering 7 Key Questions About Change Healthcare’s Cyberattack

MedCity News

The aftermath the cyberattack on Change Healthcare remains messy, with patients across the country still struggling to obtain their prescriptions. The federal government has even stepped in to help address the fallout of the attack, urging payers to quickly alleviate the digital bottlenecks that providers and pharmacies are facing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

After withdrawal, GSK touts another Blenrep combo win as analysts build blockbuster case for the myeloma ADC

Fierce Pharma

GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. | GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. And analysts are already assigning blockbuster sales figures to the medicine.

Medicine 238
article thumbnail

Blue Shield of California CEO on PBM Shakeup: ‘It’s Going to Become the Norm’

MedCity News

During a fireside chat hosted by MedCity News at ViVE, Blue Shield of California CEO Paul Markovich discussed the company’s decision to largely move away from CVS Caremark as its PBM and partner with several other companies.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Eli Lilly flags bacteria, impurity concerns in fake and compounded versions of popular GLP-1 meds

Fierce Pharma

With the swelling popularity of Eli Lilly’s diabetes med Mounjaro and its weight loss counterpart Zepbound, unauthorized copycats continue to emerge, posing a growing safety risk. | The company republished an open letter reiterating its commitment to taking legal action against scam sellers after discovering bacteria and impurities in some of the fraudulent meds.

Safety 217
article thumbnail

Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss

MedCity News

Novo Nordisk reported its weight loss pill amycretin led to greater weight loss measured at 12 weeks compared to clinical trial results for its blockbuster obesity drug Wegovy. But these results are from a small Phase 1 study and more testing is needed.

Biopharma 116

More Trending

article thumbnail

Sleep Meds Don’t Work for 9 out of 10 People with Chronic Insomnia – Here’s What Does

MedCity News

As we approach Sleep Awareness Week® 2024, which emphasizes the importance of sleep as a major contributor to a person’s overall health, it is also an important reminder to prioritize getting enough quality sleep.

Patients 108
article thumbnail

Despite Leqembi's launch pains, Eisai projects Alzheimer's med will reach $8.8B in the long run

Fierce Pharma

Despite weathering a host of launch challenges with Leqembi, Eisai still has big hopes for its amyloid-busting antibody in early Alzheimer’s disease. | By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 195
article thumbnail

Cellares Innovates With Automated Cell and Gene Therapy Platform

PharmaTech

Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.

105
105
article thumbnail

Fierce Pharma Asia—Eisai's Leqembi outlook; Sumitomo's downsizing; Kyowa Kirin's expansion

Fierce Pharma

In separate updates from Japanese drugmakers, Eisai presented new projections for its Biogen-partnered Alzheimer's disease med Leqmebi, while Sumitomo Pharma initiated a round of layoffs | Eisai presented updated projections for Alzheimer's disease drug Leqembi. Sumitomo Pharma initiated a round of layoffs in the U.S. Kyowa Kirin is building a new biologics facility in North Carolina.

Pharma 130
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Navigating the Current Funding Slowdown While Securing Capital

Pharmaceutical Commerce

In this Pharmaceutical Commerce video interview, Emma Banks, CEO of ramarketing, discusses the biggest roadblocks to the widespread adoption of novel modalities, and how new biotech companies can navigate the current funding slowdown while securing the capital crucial for their success.

article thumbnail

Gilead and MSD say weekly oral therapy controls HIV

pharmaphorum

Gilead and MSD showcase once-weekly oral HIV regimen at CROI congress, as ViiV presents new data on injectable Cabenuva in patients with low adherence to daily oral therapy

Patients 116
article thumbnail

UK manufacturing and R&D to benefit from new £360m investment

European Pharmaceutical Review

On 4 March, ahead of the Spring Budget , the UK Chancellor of the Exchequer, Jeremy Hunt, announced a significant investment package for the UK life sciences and manufacturing sectors. A total of £360 million is set to boost UK manufacturing and R&D. Joint government and industry investment of £92 million will help to expand facilities to manufacture life-saving medicines and diagnostics products.

article thumbnail

GSK scores again with Blenrep in multiple myeloma

pharmaphorum

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial. The BCMA-targeted antibody-drug conjugate (ADC), given in a regimen with pomalidomide plus dexamethasone (PomDex), was shown to be more effective at preventing disease progression or death than Johnson & Johnson’s $10 billion-a-year anti-CD38 antibody Darzalex (daratumumab) with PomDex in the head-to-head DREAMM-8 trial.

Marketing 115
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Employing MALDI-TOF MS for microbial identification in sterile drug manufacturing

European Pharmaceutical Review

A paper published in Frontiers in Microbiology has described an innovative strategy for microbial identification and contamination investigation during sterile manufacturing of drugs. The approach utilised matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) for microbial identification. Over a period of three months, two hundred ninety-two samples were collected covering multiple critical components of raw materials, personnel, environment, and production

article thumbnail

Indian Institute based research boosting pharmaceutical industrial R&D and revenue

Pharmatutor

Indian Institute based research boosting pharmaceutical industrial R&D and revenue admin Thu, 03/07/2024 - 14:23 Pharmaceutical research conducted by institutes plays a crucial role in boosting industrial research and development (R&D) in the pharmaceutical sector. These institutes, often affiliated with universities or independent research organizations, contribute significantly to advancing scientific knowledge, discovering new drugs, and fostering innovation.

article thumbnail

UK access disparity resolved as NICE backs RCC therapy

pharmaphorum

NICE decision on Ipsen’s Cabometyx and MSD’s Keytruda in first-line kidney cancer ends a disparity in access within the UK.

105
105
article thumbnail

Final Analytical Procedures Guidance Published

PharmaTech

FDA has published final guidance documents regarding validation and development of analytical procedures.

FDA 96
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Boundless Bio files IPO, and other biotech financings

pharmaphorum

Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.

102
102
article thumbnail

NHS to ensure people eligible for very high-risk breast screening are referred

PharmaTimes

Secondary breast cancer is an important risk factor after receiving radiotherapy for Hodgkin lymphoma

99
article thumbnail

J&J’s growing rare disease focus brings a potential multi-use treatment to the table

PharmaVoice

The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.

75
article thumbnail

US researchers develop algorithm test to identify aggressive ovarian cancers

PharmaTimes

Ovarian high-grade serous carcinoma is the most common form of aggressive ovarian cancer

Medicine 101
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Pharma Pulse 3/7/24: Rite Aid Enters into APA, S.E.C. Investigates OpenAI & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

Sionna raises $182m to double down in cystic fibrosis drug development

Pharmaceutical Technology

Sionna could have four candidates in clinical trials in 2024, amidst a cystic fibrosis landscape that is dominated by Vertex.

69
article thumbnail

Overcoming Veteran Employment Hurdles: Webinar with AdvaMed

MedTechVets

On January 31st we co-hosted a live webinar with AdvaMed titled “Overcoming Veteran Employment Hurdles” We had 30 participants register for the event where our three Med Tech industry panelists talked about the need for understanding how instrumental and valuable military service is, to continue to propel companies forward. Military service members and Veterans are often faced with an uphill battle as they transition to the civilian world.

article thumbnail

Gilead and Merus enter trispecific antibody discovery deal

Pharmaceutical Technology

Gilead Sciences has entered an agreement with Merus for the discovery of dual tumour-associated antigens targeting trispecific antibodies.

64
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA Approves Opdivo Plus Chemotherapy for Frontline Treatment of Unresectable, Metastatic Urothelial Carcinoma

PharmExec

Opdivo (nivolumab) plus cisplatin and gemcitabine was found to improve overall survival and progression-free survival compared with chemotherapy alone in patients with unresectable or metastatic urothelial carcinoma.

FDA 52
article thumbnail

FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor

Legacy MEDSearch

On March 5, the U.S. Food and Drug Administration (FDA) announced the clearance of Dexcom’s device, marking it as the first continuous glucose monitor available over the counter. Following this announcement, Dexcom’s shares experienced a 2.2% increase in extended trading. Known as Stelo , this device is tailored for individuals aged 18 and older who do not require insulin, who are managing diabetes via oral medications or individuals without diabetes seeking to understand how diet an

article thumbnail

The Biggest Challenges Facing Broader Adoption of Novel Cell and Gene Therapies

PharmExec

In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses the biggest challenges facing the broader adoption of novel cell and gene therapies from IQVIA's Global Trends in R&D 2024 report.

article thumbnail

Why Paper Forms Aren’t Cutting it in 2024

Penrod

Digital patient forms offer a superior solution for the healthcare sector, swiftly supplanting traditional paperwork. Here’s why. Paper Forms are Inefficient Manually filling out, sorting, and storing paper forms is a time-consuming task that hampers the efficiency and productivity of healthcare professionals. Each form requires a significant amount of time to complete, followed by the need for manual transcription.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A